Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
2011 · Nature Medicine · 514 citations
https://doi.org/10.1038/nm.2309
S
Samuel W. Brady
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
200
Papers
3.6K
Citations
27
h-index
33
i10-index
Samuel W. Brady is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Acute Lymphoblastic Leukemia research & Genomics and Rare Diseases. The author has an h-index of 27, co-authored 170 publications.
ORCID: 0000-0001-5518-7800Papers by this author
worksUncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
2022 · Cell Genomics · 343 citations
https://doi.org/10.1016/j.xgen.2022.100179
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
2019 · Blood · 293 citations
https://doi.org/10.1182/blood.2019002220
Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
1994 · The Journal of Immunology · 65 citations
https://doi.org/10.4049/jimmunol.152.3.1347
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
2019 · Neoplasia · 56 citations
https://doi.org/10.1016/j.neo.2019.06.005
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
2015 · Cancer Biology & Therapy · 53 citations
https://doi.org/10.1080/15384047.2014.1002693
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat